Skip to main content

Drug Interactions between deferasirox and enzalutamide

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

deferasirox enzalutamide

Applies to: deferasirox and enzalutamide

MONITOR: Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4. In healthy volunteers, administration of a single 160 mg oral dose of enzalutamide following multiple oral doses of the potent CYP450 2C8 inhibitor gemfibrozil resulted in a 2.2-fold increase in the composite systemic exposure (AUC) of enzalutamide plus N-desmethyl enzalutamide, with minimal effect on the peak plasma concentration (Cmax). Administration following multiple oral doses of the potent CYP450 3A4 inhibitor itraconazole resulted in a 1.3-fold increase in the composite AUC of enzalutamide plus N-desmethyl enzalutamide, with no effect on the Cmax.

MANAGEMENT: Pharmacologic response to enzalutamide should be monitored more closely whenever a CYP450 2C8 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience increased side effects such as seizure, asthenia, fatigue, diarrhea, arthralgia, musculoskeletal pain, paresthesia, hot flushes, peripheral edema, headache, dizziness, insomnia, hematuria, anxiety, and hypertension.

References

  1. (2012) "Product Information. Xtandi (enzalutamide)." Astellas Pharma US, Inc

Switch to consumer interaction data

Drug and food interactions

Moderate

deferasirox food

Applies to: deferasirox

ADJUST DOSING INTERVAL: According to product labeling, the bioavailability of deferasirox was variably increased when taken with a meal.

MANAGEMENT: To ensure consistent plasma drug levels, deferasirox should be taken on an empty stomach 30 minutes before eating preferably at the same time everyday.

References

  1. (2005) "Product Information. Exjade (deferasirox)." Novartis Pharmaceuticals

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.